

***BRAF* Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies**

EMILIE M. J. VAN BRUMMELEN,^{a,b} ANTHONIUS DE BOER,^d JOS H. BEIJNEN,^{c,d} JAN H. M. SCHELLENS^{a,b,d}

Departments of ^aClinical Pharmacology, ^bMolecular Pathology, and ^cPharmacy The Netherlands Cancer Institute, Amsterdam, The Netherlands; ^dDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. BRAF • RAS • Cetuximab • Panitumumab • Predictive biomarker • Anti-epidermal growth factor receptor

ABSTRACT

Recently, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommended that patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer could be treated with anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab only in absence of Rat-Sarcoma (*RAS*) mutations. In addition to the previously established biomarker Kirsten rat sarcoma viral oncogene homolog (*KRAS*) exon 2, cumulative evidence also shows that patients whose tumors harbor *KRAS* exons 3 or 4 and neuroblastoma rat-sarcoma viral oncogene homolog (*NRAS*) exons 2, 3, and 4 mutations are found unlikely to benefit from anti-EGFR treatment.

In line with the resistance of *RAS* mutated (mt) tumors, treatment response in *BRAF*mt tumors may also be altered given their important role in the EGFR signaling pathway.

However, *BRAF* is not recommended as predictive biomarker yet because the evidence for the impact of *BRAF* mutations on treatment outcome is considered insufficient.

This article summarizes the evidence for the impact of *BRAF* mutations on treatment outcome of anti-EGFR mAbs. Based on a review of literature, eight meta-analyses were included that consistently show that patients with *BRAF* mutations have a lack of treatment benefit of anti-EGFR mAbs. After discussing the quality and quantity of available evidence, we conclude that evidence is stronger than suggested by ESMO and ASCO. Additionally, we highlight that the quality of evidence for *BRAF* is even higher than for extended *RAS* as a biomarker. We therefore advise ESMO and ASCO to reconsider *BRAF* status as a predictive biomarker for response. *The Oncologist* 2017;22:864–872

Implications for Practice: In metastatic colorectal cancer (mCRC), therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab is indicated in absence of *RAS* mutations. Cumulative evidence shows that patients with *BRAF* mutations, who comprise 10% of the mCRC population, do not benefit from anti-EGFR-antibody treatment. Although guidelines state that evidence for *BRAF* as a predictive marker is insufficient, we highlight that the quality and quantity of evidence is higher than suggested. We therefore encourage the use of *BRAF* as a predictive marker in order to exclude patients from therapy for whom limited treatment benefit is expected.

INTRODUCTION

The RAS-RAF-MEK-ERK (MAPK) pathway plays a pivotal role in the regulation of cell proliferation, survival, and differentiation. Constitutive activation of this pathway is frequently observed in human cancers and is associated with high rates of cancer cell proliferation. Within the MAPK pathway, RAS, RAF, MEK, and ERK are key proteins in signal transduction. In tumor cells, the MAPK pathway is often constitutively activated by gain-of-function mutations in one of the signaling proteins including but not limited to RAS and RAF. In colorectal cancer (CRC), activation of the MAPK pathway is often a result of mutations in the RAS family protein

Kirsten rat sarcoma viral oncogene homolog (*KRAS*), which is found in 40% of the patients [3, 4]. Mutations occur most frequently in exon 2 (36%) and less frequently in exons 3 (2%) and 4 (2%). In addition to *KRAS*, neuroblastoma rat sarcoma viral oncogene homolog (*NRAS*) mutations occur in about 3% [3, 4]. *KRAS* and *NRAS* are very closely related, although their biological roles are slightly different. Whereas functional *KRAS* is essential for cell survival, *NRAS* is not required. Therefore, *KRAS* gain-of-function mutations may have a larger impact on tumor growth and proliferation compared with *NRAS* mutations [5].

Correspondence: Jan H. M. Schellens, M.D., The Netherlands Cancer Institute, Department of Clinical Pharmacology, Plesmanlaan 121, 1066 CX AMSTERDAM, The Netherlands & University Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Telephone: 31-0-20-512-2446; e-mail: j.schellens@nki.nl Received January 24, 2017; accepted for publication February 22, 2017; published Online First on June 2, 2017. <http://dx.doi.org/10.1634/theoncologist.2017-0031>




Figure 1. Schematic overview of the MAPK signaling pathway. Adapted with permission from van Geel et al. [66].

Abbreviations: EGFR, epidermal growth factor receptor; mAb, monoclonal antibody; MAPK, RAS-RAF-MEK-ERK.

The first effector protein of RAS is RAF, comprising c-RAF1, BRAF, and ARAF. Of these, BRAF has the most important biological function and is also most frequently mutated [6]. BRAF and RAS mutations are mutually exclusive, which highlights their functional importance [7]. Gain-of-function mutations in exon 15 result in the BRAFV600E variant in about 10% of the CRC population and induce constitutive MAPK-pathway activation [5, 8]. Other mutations that occur less frequently include the variants G469V (<0.1%), D594G (<0.3%), and K601E (unknown frequency) [6]. All mutations lead to constitutive activation of downstream proteins within the MAPK-pathway independent of upstream activation signals, yet the p.V600E variant is the strongest activator [8, 9]. BRAF mutations in CRC occur most frequently in tumors originating from the appendix and the ascending and transverse colon, defined as right-sided tumors [10–12].

In up to 90% of colorectal tumors, epidermal growth factor receptor (EGFR) is overexpressed, which renders EGFR an attractive drug target [13–16]. Upon binding of its ligands, including epidermal growth factor, betacellulin, epiregulin, and neuregulins, cell proliferation and growth are induced primarily through the MAPK and PI3K/AKT signaling pathways (Fig. 1) [17].

Cetuximab (Erbix[®] [14, 18]) and panitumumab (Vectibix[®] [15, 19]) are anti-EGFR monoclonal antibodies (mAbs) that exert their antitumor effect through inhibition of EGFR signaling. Both drugs are registered for the treatment of EGFR-expressing metastatic CRC (mCRC) after failure of first- and/or second-line therapies.

In line with the biological mechanism, several trials showed that the effects of anti-EGFR treatment are decreased when mutations downstream of EGFR are present that cause MAPK-pathway activation independent of EGFR signaling such as

mutations in KRAS (in 40%) and BRAF (in 10%) [1, 3–5, 20]. It is now generally accepted that mutations in KRAS exon 2 diminish treatment response when anti-EGFR mAbs are given as a single agent or combined with chemotherapy [1, 14, 15, 21]. More recently, several retrospective analyses showed that not only KRAS exon 2 mutations but also KRAS exons 3 and 4 and NRAS exons 2, 3, and 4 mutations are predictive biomarkers [1, 2, 7, 22–27]. Treatment guidelines for metastatic CRC now recommend upfront RAS testing before start of anti-EGFR mAb therapy [1, 2] in order to exclude patients with mutated RAS from therapy with these agents.

BRAF mutations could have comparable effects on anti-EGFR mAb treatment response as RAS mutations. BRAFV600E gain-of-function mutations comprise 80%–96% of all BRAF mutations and occur in about 10% of CRC patients [4, 6, 28]. Although several meta-analyses indicate that BRAF status may be a predictive biomarker for treatment efficacy [4, 29–32], the use of BRAF status as a predictive biomarker is not recommended yet because evidence is considered less convincing than the evidence for RAS mutations [1, 2].

This manuscript describes the evidence that is available for BRAF mutations as a predictive biomarker for response to anti-EGFR mAbs in mCRC. We will discuss the load and quality of clinical evidence for the impact of BRAF mutations on anti-EGFR mAb treatment outcomes and argue why this can be considered convincing enough to include BRAF mutation status in the panel of upfront mutation tests in anti-EGFR mAb therapy.

EVIDENCE FOR BRAF MUTATIONS AS A PREDICTIVE BIOMARKER

A PubMed search was performed to collect meta-analyses that included data of BRAF mutated (mt) patients and BRAF wild-type (wt) patients and survival outcome of treatment with the anti-EGFR mAbs cetuximab or panitumumab using the following terms: (molecular testing OR mutation) AND (BRAF OR RAF) AND survival AND EGFR AND “colorectal cancer” AND meta-analysis (full methods available in the supplemental online Appendix 1). Eight meta-analyses were identified that report on the overall response rate (ORR), progression-free survival (PFS), or overall survival (OS) of BRAFmt patients treated with anti-EGFR mAbs cetuximab or panitumumab as single agents or combined with chemotherapy. Four of these were considered high-quality reviews, and only these will be extensively discussed in this section [4, 29–31]. The results of all meta-analyses are summarized in Table 1.

De Roock et al. [4] comprehensively analyzed the relationship between different pathway mutations and treatment response and survival in mCRC patients treated with cetuximab combined with chemotherapy. The authors collected tumor samples and clinical data from 11 European investigators who had published data on cetuximab-treated mCRC patients. Finally, 761 tumor samples were analyzed for BRAF status (screened for the mutations p.D594G, p.V600E, p.V600M, and p.K601E). In 36 patients, a BRAF mutation was found, being mostly p.V600E ($n = 35$) and one p.D594G. In a selection of patients without KRAS mutations, it was found that BRAFmt patients ($n = 24$) had a significantly lower ORR (8.3%) compared with BRAFwt patients ($n = 326$, ORR 38%; OR 0.15 [95% confidence interval {CI} 0.02–0.51]) and shorter PFS (hazard ratio {HR} 3.74 [95% CI 2.44–5.75]) and OS (HR 3.03 [95% CI

Table 1. Overview of meta-analyses, which show hazard ratios for PFS, OS, and odds ratios for ORR on anti-epidermal growth factor receptor monoclonal antibody therapy by BRAF status for the KRASwt group and (°) for the KRAS unselected group

Study (n/n BRAFmt) [Ref]	BRAFmt			BRAFWt			^x BRAFmt/BRAFWt ^y BRAFWt/BRAFWt		
	PFS	OS	ORR	PFS	OS	ORR	PFS	OS	ORR
De Roock ^x (761/36) [4]							3.74 [2.44–5.75]	3.03 [1.98–4.63]	0.15 [0.02–0.51]
Pietrantonio (6,256/469) [31]	0.88 [0.67–1.14]	0.91 [0.62–1.34]	1.31 [0.83–2.08]						
Rowland ^x (3,186/351) [30]	0.86 [0.61–1.21]	0.97 [0.67–1.41]	n.d.	0.62 [0.50–0.77]	0.81 [0.70–0.95]	n.d.	1.39 ^a [0.92–2.08]	1.19 ^a [0.80–1.78]	n.d.
Therkildsen ^x (1,267/123) [29]							2.95 [1.89–4.61]	2.52 [1.39–4.56]	0.29 [0.16–0.54]
Yuan ^y (4,616/343) [32]							0.29 [0.19–0.43]	0.26 [0.20–0.36]	0.31 [0.18–0.53]
Xu ^x (2,875/246) [36]							2.41 [1.23–4.71]	2.74 [°] [2.31–3.52]	0.26 [0.07–0.98]
Wang ^x (1,352/74) [37]							2.78 [1.62–4.76]	2.54 [1.93–3.32]	0.27 [0.10–0.70]
Cui ^x (1,245/126) [38]							n.d.	n.d.	0.43 [0.16–0.75]

Four meta-analyses included only or primarily RCTs [29–31, 38] three included retrospective and prospective studies [32, 36, 37] and one included only retrospective data [4].

^aBased on re-calculation performed by the authors of this proposal.

Abbreviations: KRAS, Kirsten rat sarcoma viral oncogene homolog; mt, mutated; n, number of patients; n BRAFmt, number of patients with a BRAF mutation; n.d., not described; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; wt, wild type.

1.98–4.63]). The association between disease control and BRAF status was significant in multivariate analysis (adjusted OR BRAFmt vs. BRAFWt 0.059; $p < .0001$), as was the association with KRAS, NRAS, and PIK3CA exon 20. Still, 2 out of 24 patients had a response to treatment despite BRAF mutations. The authors report that one of these had a p.D594G mutation that leads to weaker activation of the MAPK pathway compared with p.V600E mutations [33]. The other responder had a low copy number of BRAFV600Emt genes that may explain the sensitivity to cetuximab. The authors conclude that the response rate of 24.4% in an unselected population could be increased to 36.3% in a KRASwt population and further to 38.4% in KRASwt and BRAFWt patients [4]. Another 1.5% ORR improvement could be achieved by NRAS testing according to their results. This study highlighted the importance of BRAF in addition to KRAS status in treatment with anti-EGFR mAbs. Several meta-analyses have been performed to confirm the findings of De Roock et al.

Pietrantonio et al. [31] performed a meta-analysis of randomized controlled trials (RCTs) to examine the effect of anti-EGFR mAbs on PFS, OS, and ORR in BRAFmt/KRASwt advanced CRC. Nine phase III trials and one phase II trial were included that compared anti-EGFR mAbs as monotherapy or added to chemotherapy with chemotherapy or best supportive care in advanced KRASwt CRC. In total, these comprised 6,256 patients on first-line (six trials) and second-line treatment (two trials) or who were chemo-refractory (two trials). The authors show that patients with BRAFmt CRC ($n = 469$) do not have a significant benefit in PFS (HR PFS benefit 0.88 [95% CI 0.67–1.14]), OS (HR OS 0.91 [95% CI 0.62–1.34]), or ORR (OR 1.31 [95% CI 0.83–2.08]) from treatment with anti-EGFR mAbs. All mutations comprised p.V600E mutations except for 21 patients (13%) in the trial from Smith et al. who had the p.D594G

mutation [34]. The response rate of patients with BRAFmt varied from 10.8% to 52.2% on anti-EGFR mAbs compared with 6.4% to 40% on chemotherapy. Based on these results, BRAFmt patients seem to have modest responses to anti-EGFR mAbs, yet, overall, a significant response rate and survival benefit is lacking in this population [31]. A drawback of this meta-analysis is that a comparison with BRAFWt patients has not been made.

Rowland et al. [30] reviewed RCTs that evaluated the effect of BRAF mutations on treatment benefit (OS and PFS) from anti-EGFR mAbs for KRAS exons 2 and 3 wt metastatic CRC mCRC. All of the included trials have also been reviewed by Pietrantonio et al. [31]. However, Rowland et al. excluded the trials by Tveit et al. [35] and Stintzing et al. [24], probably because the former did not provide data on PFS and OS and the latter had bevacizumab with FOLFIRI as control treatment instead, which did not meet the inclusion criteria. The review by Rowland et al. thus differs from Pietrantonio et al. by inclusion criteria but moreover by their statistical tests [30, 31].

Seven articles covering eight RCTs were included in which 3,168 KRASwt patients were treated with cetuximab or panitumumab (four studies each) added to chemotherapy or with chemotherapy alone. About 11% of the tumors harbored a BRAF mutation ($n = 351$), of which 94% ($n = 330$) were p.V600E mutations and 6% ($n = 21$) were p.D594G mutations [34]. Rowland et al. not only reported outcomes for the BRAFmt subgroup but also compared BRAFmt patients with BRAFWt patients. Results show a lack of PFS benefit in the BRAFmt group (HR PFS benefit 0.86 [95% CI 0.61–1.21]), whereas patients with BRAFWt had significant benefit (HR PFS benefit 0.62 [95% CI 0.50–0.77]) from addition of anti-EGFR mAbs to chemotherapy. The interaction test (PFS HR BRAFmt/PFS HR BRAFWt) showed a close to significant difference ($p = .07$). For OS, BRAFmt patients (HR 0.97 [95% CI 0.67–1.41]) also had no

Table 2. Summary of the results from five randomized clinical trials which report on the effects of *KRAS* exon 2 mutations^a

Study [Ref] (n)	Treatment	<i>KRAS</i> exon 2 wild type		<i>KRAS</i> exon 2 mutation	
		PFS (months)	ORR	PFS (months)	ORR
Van Cutsem [22] (n = 540)	Cetuximab + FOLFIRI	9.9	59.3	7.6	36.2
	vs. FOLFIRI	8.7	43.2	9.1	40.2
	HR/OR	0.68 ^b	1.37 ^b	1.07	0.9
Bokemeyer [13] (n = 233)	Cetuximab + FOLFOX	7.7	60.7	5.5	32.7
	vs. FOLFOX	7.2	37.0	8.6	48.9
	HR/OR	0.57 ^b	2.54 ^b	1.83 ^b	0.51
Punt [67] (n = 501)	Cetuximab + CAPOX-B	10.5	n.d.	8.6	n.d.
	vs. CAPOX-B	10.7	n.d.	12.5	n.d.
	HR/OR	n.d.	n.d.	n.d.	n.d.
Amado [39] (n = 427)	Panitumumab	12.3	17	7.4	0
	vs. BSC	7.3	0	7.3	0
	HR/OR	0.45 ^b	n.d.	0.99	n.d.
Karapetis [57] (n = 394)	Cetuximab	3.7	12.8	1.8	1.2
	vs. BSC	1.9	0	1.8	0
	HR/OR	0.4 ^b	n.d.	0.99	n.d.

^aReferred to in the American Society of Clinical Oncology's clinical opinion update 2009 [21].

^b $p < .05$

Abbreviations: BSC, best supportive care; CAPOX, capecitabine, oxaliplatin; FOLFIRI, 5-fluorouracil, folinic acid, irinotecan; FOLFOX, 5-fluorouracil, folinic acid, oxaliplatin; HR, hazard ratio; *KRAS*, Kirsten rat sarcoma viral oncogene homolog; n.d., not described; OR, odds ratio; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.

benefit, whereas *BRAF*^{wt} patients (HR 0.81 [95% CI 0.70–0.95]) had significantly improved OS. The interaction test for OS was not significant ($p = .43$). For both PFS and OS, the difference between *BRAF*^{mt} and *BRAF*^{wt} patients was bigger in the second-line setting, showing a very strong trend towards significance (interaction test PFS $p = .05$; OS $p = .38$). The authors conclude that based on the nonsignificant interaction test values, the effect of *BRAF* mutations on PFS and OS cannot be confirmed [30].

However, it is of great importance to note that the interaction test for PFS was very close to significance. To allow proper interpretation of the p value (.07), CIs of the interaction test value should be taken into account. However, these were not provided by the authors. Based on our re-estimation, as described in the methods section, the 95% CI for the interaction on PFS should range from 0.92 to 2.08. This underscores that there is a high chance that anti-EGFR mAbs have a different effect on PFS in *BRAF*^{mt} patients. To summarize, these results confirm a significant lack of PFS benefit of anti-EGFR mAbs treatment in *BRAF*^{mt} patients, which is relevantly though not significantly different from the *BRAF*^{wt} patients.

Another meta-analysis was performed by Therkildsen et al. [29], who reviewed the impact of alterations in *KRAS* other than exon 2, *NRAS*, *BRAF*, *PIK3CA*, and *PTEN* on clinical benefit of anti-EGFR treatment combined with chemotherapy in *KRAS* exon 2 wt patients in 21 RCTs and one nonrandomized trial. Among 1,267 patients treated with cetuximab or panitumumab in first to greater than fourth setting mostly, *BRAF* mutations were detected in 123 patients, all of which were p.V600E

except for one p.K601E variant. *BRAF*^{mt} patients were found to have significantly lower ORR (OR ORR 0.29 [95% CI 0.16–0.54]) and shorter PFS (HR 2.95 [95% CI 1.89–4.61]) and OS (HR 2.52 [95% CI 1.39–4.56]) compared with *BRAF*^{wt} patients. The authors also report that the response rate can be increased from 37.6% on average in *KRAS*^{wt} selected patients to 39% in *KRAS*^{wt}/*BRAF*^{wt} selected patients.

In our opinion, these meta-analyses provide high-quality clinical evidence for the lack of efficacy of anti-EGFR mAb treatment on response and survival endpoints for patients with *BRAF*^{mt} tumors. Supporting evidence can be found in four meta-analyses that included survival endpoints based on retrospective studies, mainly [32, 36, 37], or that included response rate as an endpoint only (Table 1) [38].

Evidence for *BRAF* Compared with *RAS*

Initially, Erbitux[®] and Vectibix[®] were registered for patients with EGFR-expressing metastatic CRC only in presence of *KRAS* exon 2 wt. This was based on seven pivotal trials with cetuximab that show that the *KRAS* exon 2 mutated population had no benefit on primary endpoints ORR, PFS, or OS [14, 15, 39]

This is supported by a review of five RCTs that was performed by the American Society of Clinical Oncology (ASCO) [21]. The authors showed that all five trials, comprising 2,095 patients, consistently detected a lack of benefit from treatment with anti-EGFR mAbs in 720 patients with *KRAS* exon 2 mutations in terms of PFS and ORR (Table 2), whereas *KRAS* exon 2 wt patients did have significant benefit.

Table 3. Summary of the data from meta-analyses addressing the effect of *KRAS* exons 2, 3, and 4 mutations referred to in the American Society of Clinical Oncology's clinical opinion update 2015 [1]

Study [Ref] (n)	Treatment	<i>KRAS</i> exons 2, 3, and 4 wild type		<i>KRAS</i> exons 2,3,4 mutation	
		HR PFS	HR OS	HR PFS	HR OS
Adelstein [40] (n = 8,924)	P/C vs. SOC or P/C + SOC vs. SOC Interaction: <i>KRAS</i> wt/ <i>KRAS</i> mt	0.80 [0.64–0.99] 0.71 [0.57–0.90]	n.d.	1.11 [0.97–1.27]	n.d.
Dahabreh [41] (n=1,945)	P/C +- SOC vs. BSC or SOC Interaction: <i>KRAS</i> mt/ <i>KRAS</i> wt	n.d.	n.d.	n.d.	n.d.
Lin [42] (n = 5,325)	P/C +SOC vs. SOC	0.66 [0.53–0.82]	n.d.	1.07 [0.91–1.27]	n.d.
Loupakis [43] (n = 6,609)	P/C+ SOC vs. SOC	0.91 [0.84–0.99]	0.95 [0.87–1.04]	1.13 [1.03–1.25]	1.04 [0.95–1.13]
Petrelli [44] (n = 484)	P/C+ SOC vs. SOC	0.68 [0.53–0.87]	0.88 [0.65–1.20]	n.d.	n.d.
Petrelli [45] (n = 3,254)	P/C+ SOC vs. SOC	0.65 [0.51–0.83]	0.84 [0.73–0.98]	n.d.	n.d.
Qiu [46] (n = 2,188)	C + SOC vs. SOC Interaction: <i>KRAS</i> mt/ <i>KRAS</i> wt	5.8 1.94 [1.62–2.33]	6.9 2.17 [1.72–2.74]	3.0	13.5
Vale [47] (n = 5,966)	P/C+ SOC vs. SOC Interaction: <i>KRAS</i> wt/ <i>KRAS</i> mt	0.83 [0.76–0.90] 0.78 [0.68–0.89]	0.89 [0.82–0.97] 1.04 [0.95–1.15]	1.06 [0.96–1.17]	1.04 [0.95–1.15]
Zhang [48] (n = 2,912)	P/C+ SOC vs. SOC	0.64 [0.50–0.84]	0.84 [0.64–1.11]	1.37 [0.81–2.31]	1.03 [0.74–1.44]
Ibrahim [49] (n = 2,115)	P + SOC vs. SOC	0.58 [0.36–0.93]	0.90 [0.76–1.05]	n.d.	n.d.

All meta-analyses included RCTs only, except for Qui [46] and Dahabrah et al. [41] who included also retrospective and observational studies.

Abbreviations: BSC, best supportive care; C, cetuximab; HR, hazard ratio; *KRAS*, Kirsten rat sarcoma viral oncogene homolog; n, number of patients; n.d., not described; OS, overall survival; P, panitumumab; PFS, progression-free survival; RCT, randomized controlled trial; SOC, standard of care.

In October 2015, ASCO recommended to extend upfront testing of *KRAS* exon 2 with *KRAS* exons 3 and 4 and *NRAS* exons 2, 3, and 4 [1]. In July 2016, the European Society for Medical Oncology (ESMO) supported this “extended *RAS*” testing in their consensus guideline on the management of metastatic CRC [2]. In Europe, these findings were incorporated in the product labels of Erbitux[®] and Vectibix[®], which state that the benefit-risk ratio of treatment is negative for patients with *KRAS* or *NRAS* exons 2, 3, or 4 mutations [18, 19].

As supportive evidence for *KRAS* exons 2, 3, and 4 testing, ASCO referred to ten [40–49] meta-analyses and two [50, 51] health technology assessment reports that reviewed 137 primary studies with 19,543 patients. Table 3 summarizes findings of these ten meta-analyses. In all studies, a statistically significant PFS benefit in patients without *KRAS* exons 2, 3, or 4 mutations was found, whereas benefit was not significant in *KRAS* exons 2, 3, and 4 mutants. The effects of *KRAS* mutations on OS were less consistent. Five out of the 13 trials detected no statistically significant difference in OS between *KRAS*mt and *KRAS*wt patients treated with anti-EGFR mAbs. This is mainly due to lack of consistent OS benefit when adding anti-EGFR mAbs to standard of care in the overall and *KRAS*wt population. In *KRAS*wt patients, OS benefit was detected in only 6 out of 13 trials [45–47, 49–51].

In contrast to the evidence for *KRAS* exons 2, 3, and 4, only five articles report on the impact of *KRAS* exons 3 and 4 and *NRAS* mutations by itself (Table 3) [2, 7, 22, 25–27]. Although these five trials consistently show that patients with *RAS*

mutations do not have significant treatment benefit, it should be noted that this is based on a small group with *RAS* mutations other than *KRAS* exon 2. The subgroup of *KRAS* exons 3 and 4 and *NRAS* exons 2, 3, and 4 mutated patients comprises only 10%–20% of the study populations, which were 360 patients in total. To increase the power, most studies merge patients with any *RAS* mutation into one or two groups. This supports extended *RAS* testing but does not provide evidence on the effect of *KRAS* exons 3 and 4 and *NRAS* mutations by itself. In addition, the detected lack of OS benefit in the *RAS*mt subgroup is of limited value in three out of five trials because the *RAS*wt group did not have OS benefit either, and no significant interaction has been confirmed.

Despite these limitations, evidence was considered convincing enough by ASCO and ESMO to recommend upfront *KRAS* and *NRAS* exons 2, 3, and 4 mutation testing, so that only patients whose tumors do not harbor mutations in these exons will be given anti-EGFR mAb therapy [1, 2].

DISCUSSION

Strong Evidence for Impact of *BRAF*mt on Anti-EGFR mAb Treatment Outcome

ASCO's and ESMO's most recent guidelines for the treatment of mCRC posit that there is currently insufficient evidence to recommend *BRAF* mutations as a biomarker for response to

Table 4. Overview of RCTs showing hazard ratios for PFS and OS stratified by RAS status^a

Author [Ref]	Treatment	No RAS mutation		KRAS exon 2 mutation		KRAS exon 2 wild type, KRAS exons 3 and 4 or NRAS exons 2, 3, and 4 mutations		Any RAS mutation	
		PFS	OS	PFS	OS	PFS	OS	PFS	OS
Douillard [7] (n = 1,060)	P + FOLFOX4 vs. FOLFOX4	0.72 [0.58–0.90]	0.78 [0.62–0.99]	1.29 [1.04–1.62]	1.24 [0.98–1.57]	1.28 [0.79–2.07]	1.29 [0.79–2.1]	1.31 [1.07–1.6]	1.25 [1.02–1.55]
Van Cutsem [22] (n = 639)	C + FOLFIRI vs. FOLFIRI	0.56 [0.41–0.76]	0.69 [0.54–0.88]	n.d.	n.d.	0.81 [0.39–1.67]	1.22 [0.69–2.16]	1.10 [0.85–1.42]	1.05 [0.86–1.28]
Schwartz-berg [27] (n = 285)	P + mFOLFOX6 vs. B + mFOLFOX6	0.65 [0.44–0.96]	0.63 [0.39–1.02]	n.d.	n.d.	1.39 [0.73–2.64]	0.41 [0.19–0.87]	n.d.	n.d.
Peeters [26] (n = 1,014)	P + FOLFIRI vs. FOLFIRI	0.70 [0.54–0.91]	0.81 [0.63–1.03]	0.85 [0.68–1.06]	0.94 [0.76–1.15]	0.89 [0.56–1.42]	0.83 [0.53–1.29]	0.86 [0.70–1.05]	0.91 [0.76–1.10]
Bokemeyer [25] (n = 118)	C + FOLFOX4 vs. FOLFOX4	0.53 [0.27–1.04]	0.94 [0.56–1.56]	n.d.	n.d.	0.77 [0.28–2.08]	1.09 [0.44–2.68]	1.54 [1.04–2.29]	1.29 [0.91–1.84]

^aReferred to in the American Society of Clinical Oncology's clinical opinion updates of 2009 and 2015 [1, 21].

Abbreviations: B, bevacizumab; C, cetuximab; FOLFIRI, folinic acid + fluorouracil + irinotecan; FOLFOX, folinic acid + fluorouracil + oxaliplatin; KRAS, Kirsten rat sarcoma viral oncogene homolog; n, population evaluable for RAS status; n.d., not described; NRAS, neuroblastoma rat sarcoma viral oncogene homolog; OS, overall survival; P, panitumumab, PFS, progression-free survival; RAS, rat sarcoma viral oncogene homolog.

anti-EGFR therapy [52]. ESMO's guideline refers to three clinical trials [53–55] and two meta-analysis [30, 31], which show conflicting results. The authors of the guideline suggest that the evidence for *BRAF* mutations as a predictive biomarker for anti-EGFR therapy in later lines is accumulating, but the role in earlier treatment lines is uncertain [2]. It is therefore recommended that *BRAF* status is used as a prognostic marker or as a selection tool for clinical trials only. Based on our literature review, the evidence for the use of *BRAF* as a predictive marker may be stronger than suggested.

All eight meta-analyses that were reviewed, covering first-line and second-line settings (supplemental online Table 1), consistently show that *BRAF*mt patients do not have significant benefit from anti-EGFR mAbs in terms of ORR, PFS, and OS [30, 31], and when compared with *BRAF*wt patients, they have significantly less ORR, PFS, and OS benefit (Table 1) [4, 29, 32, 36, 37]. A significant interaction between *BRAF* and outcome has been confirmed in five meta-analyses [4, 29, 32, 36, 37]. Because both cetuximab and panitumumab were registered mainly based on PFS benefit [7, 18, 19, 22, 25–27], the detected lack of PFS benefit in *BRAF*mt patients should warrant the use in this population.

Only Rowland et al. reported a nonsignificant interaction between the *BRAF*wt and *BRAF*mt group on both PFS and OS, although the result for PFS was close to significant ($p = .07$). This finding should be interpreted in context with the power to detect significant differences. Results of Rowland et al. are based on a group of 3,096 patients. Although this is one of the three most extensive meta-analyses, it provides a power of 19% [56], whereas a sample size of 6,500 patients is required to detect a significant interaction effect with a power of 80% (calculation provided in methods section) [30].

Overall, the load of strong clinical evidence for *BRAF* mutations as a biomarker is based on a population of 628 patients with *BRAF* mutations [4, 29, 31]. In comparison, the evidence for *KRAS* exons 3 and 4 and *NRAS* exons 2, 3, and 4 comes from only five studies with 360 patients with *RAS* mutations other than *KRAS* exon 2 [7, 22]. The lack of treatment benefit in this group guided ASCO's and ESMO's clinical opinion on extended *RAS* testing, while a significant interaction between *KRAS* exons 3 and 4/*NRAS* exons 2, 3, and 4 mutant and wt patients has not been confirmed. Based on this, the evidence for the impact of *BRAF* mutations on efficacy of anti-EGFR mAb treatment as a single agent or combined with chemotherapy can be considered stronger than for *KRAS* and *NRAS* mutations.

Biologically, it is possible that *BRAF*mt tumors respond to anti-EGFR treatment due to tumor heterogeneity, low copy numbers, and/or a varying potency of *BRAF* mutations to activate the MAPK pathway. As an example, the p.V600E mutation is a strong pathway activator, whereas the p.D594G is less activating and may still allow responses.

Risks of Using *BRAF* as a Predictive Marker

If upfront molecular testing of *BRAF* will be applied, it is expected that 10% of the mCRC population will be identified as *BRAF*mt and will be excluded from anti-EGFR mAb therapy. The

most important risk of the use of *BRAF* as a predictive biomarker lies in withholding *BRAF*mt patients from a potentially effective treatment with anti-EGFR mAbs. In *BRAF*mt patients, response rates of 8.3% [4] to 18% [36] have been reported compared with 38% [4] to 42.4% [36] in *BRAF*wt patients. Although a direct effect of anti-EGFR mAbs cannot be ruled out, the responses may also be induced by backbone chemotherapy, which was administered in the majority of trials and which induced response rates of 13%–40% [31]. This is supported by the finding that response rates in *BRAF*mt patients are higher when anti-EGFR mAbs are combined with chemotherapy (ORR 8.3%–18% [4, 36]) compared with monotherapy (ORR 1.2% [57]). As a comparison, it should also be noted that in patients with *KRAS* exon 2 mutations relevant response rates of 33%–36% [13, 54] have been observed on anti-EGFR treatment added to chemotherapy (Table 2) as well as incidental responses on monotherapy [18]. Yet, this did not hinder implementation of *KRAS* as a biomarker.

Biologically, it is possible that *BRAF*mt tumors respond to anti-EGFR treatment due to tumor heterogeneity, low copy numbers, and/or a varying potency of *BRAF* mutations to activate the MAPK pathway [8]. As an example, the p.V600E mutation is a strong pathway activator, whereas the p.D594G is less activating and may still allow responses [58, 59]. It is unlikely that this plays a big role in the study results as described in this review because the majority of patients had *BRAF*V600E mutations. However, it may explain specific cases of responders. Importantly, preclinical and clinical evidence shows that *BRAF* mutations may sensitize tumors to anti-EGFR treatment when combined with targeted agents such as *BRAF* and *MEK* inhibitors [60–62]. The potential of these combinations is currently studied in clinical trials [62, 63]. The use of *BRAF* as predictive marker as discussed in this review therefore only applies to anti-EGFR monotherapy or combined with chemotherapy.

Limitations

The robustness of evidence for *BRAF* mutations as a predictive biomarker is limited by some factors.

Firstly, compared with *KRAS*, *BRAF* mutations may have a less pronounced predictive effect. Whereas patients with *KRAS* exons 2, 3, and 4 mutations have 10%–30% higher risk of progression during treatment with anti-EGFR mAbs compared with control treatment (Tables 3 and 4), the effect of *BRAF* mutations seems smaller. This is based on PFS HRs with a wider CI in patients with *BRAF*mt on anti-EGFR therapy (Table 1) compared with patients with *KRAS* exons 2, 3, and 4 mutations (Table 3). However, it should be noted that the evidence for extended *RAS* testing was based on groups in which patients with *KRAS* exons 3 and 4 and *NRAS* exons 2, 3, and 4 mutations were merged. The effect of these mutations are even more convincing if *KRAS* exon 2 mutations are also included (any *RAS* mutation, Table 4). Merging all *RAS* mutations is needed to improve the power of the study. However, when comparing the load of evidence for extended *RAS* with the load of evidence for *BRAF*, it should be taken into account that the group of *BRAF*mt patients is always analyzed separately, resulting in a less evident result. Merging this group with *RAS*mt patients would improve the power, but the relevance is questionable because of the different biology of the mutations.

Secondly, the impact of patient selection by *BRAF* status on OS remains uncertain. Because even in *RAS*wt and *BRAF*wt

patients, the OS benefit of anti-EGFR mAbs is not consistently confirmed among different studies (Table 4); OS seems an unreliable endpoint to assess the predictive value of *BRAF* for outcomes on anti-EGFR therapy. Therefore, the effects on PFS should guide decision-making instead of effects on OS. In addition, uncertainties about the predictive value of *BRAF* may be a result of other predictive biomarkers beyond *KRAS* and *BRAF*. Recent evidence highlights the importance of primary sidedness on CRC prognosis and response [12]. Right- and left-sided tumors have a different biological origin, resulting in different molecular characteristics. While left-sided tumors are associated with EGFR overexpression, right-sided tumor more often carry *BRAF* mutations [10, 12] and are associated with poorer response and a shorter survival independent of treatment [11, 64]. Although sidedness has been identified as an independent biomarker [11], the association between sidedness, *KRAS* and *BRAF* status, and response to anti-EGFR mAbs is still to be clarified.

Moreover, cumulating evidence shows that in absence of a confirmed *BRAF* mutation, a similar gene expression profile can be present, referred to as *BRAF*-like tumors. *BRAF*-like tumors have comparable characteristics as *BRAF*mt tumors, leading to treatment resistance by constitutive MAPK-pathway activation independent of EGFR signaling. Future clinical validation studies should reveal whether the evidence for *BRAF* status as a predictive biomarker could become stronger by including *BRAF*-like gene signatures [65].

Future clinical validation studies should reveal whether the evidence for *BRAF* status as a predictive biomarker could become stronger by including *BRAF*-like gene signatures

CONCLUSION

Recent guidelines recommend upfront extended *RAS* testing in mCRC patients in order to exclude patients with *KRAS* exons 2, 3, and 4 and *NRAS* exons 2, 3, and 4 mutations from therapy with anti-EGFR mAbs. As outlined in this review, the evidence for *BRAF* testing is of an even higher level than the evidence for extended *RAS* testing. Across all studies, no ORR, PFS, or OS benefit could be detected in any *BRAF*mt subgroup. Moreover, significant interactions of *BRAF* status with treatment outcome have been observed. This review highlights that despite limitations in power and effect size, the current evidence should be enough to draw conclusions.

Based on consistent lack of benefit of anti-EGFR mAb therapy in *BRAF*mt patients, it is advised that anti-EGFR mAb therapy is excluded for these patients. The authors therefore encourage ASCO and ESMO to reconsider *BRAF* as a predictive biomarker, as this will help in selecting patients for whom maximum treatment benefit is expected.

AUTHOR CONTRIBUTIONS

Conception/Design: Jan H. M. Schellens, Emilie M. J. van Brummelen

Collection and/or assembly of data: Jan H. M. Schellens, Emilie M. J. van Brummelen

Data analysis and interpretation: Emilie M. J. van Brummelen, Anthonius de Boer, Jos H. Beijnen, Jan H. M. Schellens

Manuscript writing: Jan H. M. Schellens, Emilie M. J. van Brummelen
Final approval of manuscript: Emilie M. J. van Brummelen, Anthonius de Boer,
 Jos H. Beijnen, Jan H. M. Schellens

DISCLOSURES

The authors indicated no financial relationships.

REFERENCES

- Allegra CJ, Rumble RB, Hamilton SR et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J Clin Oncol* 2016;34:179–185.
- Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016;27:1386–1422.
- Welcome Trust Sanger Institute. Cosmic: Cancer Browser. Available at https://cancer.sanger.ac.uk/cosmic/browse/tissue#sn=large_intestine&ss=all&hn=all&sh=all&in=t&src=tissue&all_data=n. Accessed August 18, 2016.
- De Roox W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. *Lancet Oncol* 2010;11:753–762.
- Downward J. Targeting RAS signalling pathways in cancer therapy. *Nat Rev Cancer* 2003;3:11–22.
- Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. *Nat Rev Mol Cell Biol* 2015;16:281–298.
- Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013;369:1023–1034.
- Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949–954.
- Stover D. BRAF c. 1781A>G (D594G) mutation in colorectal cancer. My Cancer Genome. Available at 2015. Available at <https://www.mycancergenome.org/content/disease/colorectal-cancer/braf/148/>. Accessed March 30, 2017.
- Missiaglia E, Jacobs B, D'Ario G et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. *Ann Oncol* 2014;25:1995–2001.
- Tejpar S, Stintzing S, Ciardiello F et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. *JAMA Oncol* 2016 [Epub ahead of print].
- Ciombor KK, Goldberg RM. Primary tumor sidedness as prognostic and predictive biomarker in metastatic colorectal cancer. *JAMA Oncol* 2016 [Epub ahead of print].
- Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009;27:663–671.
- Bristol-Myers Squibb. Product Label Erbitux (cetuximab). 2009. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s0228lbl.pdf. Accessed August 4, 2016.
- Amgen Inc. Product Label Vectibix (panitumumab). 2006. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdf. Accessed August 4, 2016.
- Saif MW. Colorectal cancer in review: The role of the EGFR pathway. *Expert Opin Investig Drugs* 2010;19:357–369.
- Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene* 2006;366:2–16.
- European Medicines Agency. Erbitux (cetuximab) Eur. Public Assess. Rep. 2015. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdf. Accessed March 30, 2017.
- European Medicines Agency. Vectibix (panitumumab) Eur. Public Assess. Rep. 2015. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000741/WC500047710.pdf. Accessed March 30, 2017.
- Armaghany T, Wilson JD, Chu Q et al. Genetic alterations in colorectal cancer. *Gastrointest Cancer Res* 2012;5:19–27.
- Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J Clin Oncol* 2009;27:2091–2096.
- Van Cutsem E, Lenz HJ, Köhne CH et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *J Clin Oncol* 2015;33:692–700.
- Sorich MJ, Wiese MD, Rowland A et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. *Ann Oncol* 2015;26:13–21.
- Stintzing S, Modest DP, Rossius L et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. *Lancet Oncol* 2016;17:1426–1434.
- Bokemeyer C, Köhne CH, Ciardiello F et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. *Eur J Cancer* 2015;51:1243–1252.
- Peeters M, Oliner KS, Price TJ et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. *Clin Cancer Res* 2015;21:5469–5479.
- Schwartzberg LS, Rivera F, Karthaus M et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal. *J Clin Oncol* 2014;32:2240–2247.
- Barras D. BRAF mutation in colorectal cancer: An update. *Biomark Cancer* 2015;7:9–12.
- Therkildsen C, Bergmann TK, Henrichsen-Schnack T et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. *Acta Oncol* 2014;53:852–864.
- Rowland A, Dias MM, Wiese MD et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. *Br J Cancer* 2015;112:1888–1894.
- Pietrantonio F, Petrelli F, Coinu A et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. *Eur J Cancer* 2015;51:587–594.
- Yuan ZX, Wang XY, Qin QY et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: A meta-analysis. *PLoS One* 2013;8:e65995.
- Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* 2004;116:855–867.
- Smith CG, Fisher D, Claes B et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. *Clin Cancer Res* 2013;19:4104–4113.
- Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. *J Clin Oncol* 2012;30:1755–1762.
- Xu Q, Xu AT, Zhu MM et al. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A meta-analysis. *J Dig Dis* 2013;14:409–416.
- Wang Q, Hu W, Song QB et al. BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: A meta-analysis. *Chinese Med Sci J* 2014;29:197–203.
- Cui D, Cao D, Yang Y et al. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: A meta-analysis of randomized studies. *Mol Biol Rep* 2014;41:1291–1298.
- Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626–1634.
- Adelstein BA, Dobbins TA, Harris CA et al. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. *Eur J Cancer* 2011;47:1343–1354.
- Dahabreh IJ, Terasawa T, Castaldi PJ et al. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. *Ann Intern Med* 2011;154:37–49.
- Lin AY, Buckley NS, Lu AT et al. Effect of KRAS mutational status in advanced colorectal cancer on

the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: A systematic review and meta-analysis. *Clin Colorectal Cancer* 2011;10:63–69.

43. Loupakis F, Cremolini C, Salvatore L et al. Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies. *Cancer* 2012;118:1523–1532.

44. Petrelli F, Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: A meta-analysis. *Int J Colorectal Dis* 2012;27:997–1004.

45. Petrelli F, Borgonovo K, Cabiddu M et al. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: A meta-analysis. *Int J Colorectal Dis* 2011;26:823–833.

46. Qiu LX, Mao C, Zhang J et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies. *Eur J Cancer* 2010;46:2781–2787.

47. Vale CL, Tierney JF, Fisher D et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. *Cancer Treat Rev* 2012;38:618–625.

48. Zhang L, Ma L, Zhou Q. Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: A meta-analysis. *Int J Colorectal Dis* 2011;26:1025–1033.

49. Ibrahim EM, Abouelkhair KM. Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: A meta-analysis of randomized clinical trials. *Med Oncol* 2011;28:S310–S317.

50. Hoyle M, Crathorne L, Peters J et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-

line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): A systematic review and economic model. *Health Technol Assess* 2013;17:1–237.

51. Health Quality Ontario. KRAS testing for anti-EGFR therapy in advanced colorectal cancer: An evidence-based and economic analysis. *Ont Health Technol Assess Ser* 2010;10:1–49.

52. Onclive. New Molecular Testing Guidelines Pending for Colorectal Cancer. 2015. Available at <http://www.onclive.com/publications/oncology-live/2015/july-2015/new-molecular-testing-guidelines-pending-for-colorectal-cancer>. Accessed August 19, 2016.

53. Seymour MT, Brown SR, Middleton G et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. *Lancet Oncol* 2013;14:749–759.

54. Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated Analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011;29:2011–2019.

55. Peeters M, Oliner KS, Parker A et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. *Clin Cancer Res* 2013;19:1902–1912.

56. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2014. Available at <http://www.r-project.org/>. Accessed March 30, 2017.

57. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359:1757–1765.

58. Perrone F, Lampis A, Orsenigo M et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. *Ann Oncol* 2008;20:84–90.

59. Pegram MD, Borges VF, Ibrahim N et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. *Breast Cancer Res* 2009;11:R73.

60. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. *Nature* 2012;483:100–103.

61. Yaeger R, Cercek A, O'Reilly EM et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. *Clin Cancer Res* 2015;21:1313–1320.

62. Tabernero J, Van Geel R, Kyrre Guren T et al. Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFM CRC). *J Clin Oncol* 2016;34:3544a.

63. Atreya CE, van Cutsem E, Bendell JC et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFM) metastatic colorectal cancer (mCRC). *J Clin Oncol* 2015;33:103a.

64. Venook A, Niedzwiedzki D, Innocenti F, et al. Impact of primary tumor location (1°) on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). *J Clin Oncol* 2016;34:3504a.

65. Vecchione L, Gambino V, Raaijmakers J et al. A vulnerability of a subset of colon cancers with potential clinical utility. *Cell* 2016;165:317–330.

66. van Geel RM, Beijnen JH, Bernards R et al. Treatment individualization in colorectal cancer. *Curr Colorectal Cancer Rep* 2015;11:335–344.

67. Tol J RCPC. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). *J Clin Oncol* 2008;26:LBA4011a.



See <http://www.TheOncologist.com> for supplemental material available online.



This article is available for continuing medical education credit at CME.TheOncologist.com.